Pith. sign in

Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

1 Pith paper cite this work. Polarity classification is still indexing.

1 Pith paper citing it

citation-role summary

background 1

citation-polarity summary

fields

stat.AP 1

years

2025 1

verdicts

CONDITIONAL 1

roles

background 1

polarities

unclear 1

representative citing papers

citing papers explorer

Showing 1 of 1 citing paper.